Author:
Morgan Robert J.,Synold Timothy W.,Longmate Jeffrey A.,Quinn David I.,Gandara David,Lenz Heinz-Josef,Ruel Christopher,Xi Bixin,Lewis Michael D.,Colevas A. Dimitrios,Doroshow James,Newman Edward M.
Funder
National Institutes of Health
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference37 articles.
1. Margolin K, Synold T, Longmate J, Doroshow JH (2001) Methodologic guidelines for the design of high-dose chemotherapy regimens. Biol Blood Marrow Transpl 7(8):414–432
2. Kraljevic S, Sedic M, Scott M, Gehrig P, Schlapbach R, Pavelic K (2006) Casting light on molecular events underlying anti-cancer drug treatment: what can be seen from the proteomics point of view? Cancer Treat Rev 32(8):619–629
3. Collins I, Workman P (2006) New approaches to molecular cancer therapeutics. Nat Chem Biol 2(12):689–700
4. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsk BM, Palme MH, Habgood GJ, Singer LA, DiPietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61(3):1013–1021
5. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4(7):1086–1095
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献